Biotech Acquisition Company (BIOT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
545 WEST 25TH STREET NEW YORK, NY 10001 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2022 MRQ | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 91,407 | ||||
| Cash and cash equivalents | 91,407 | ||||
| Prepaid expense | 208,056 | ||||
| Deferred costs | 89,500 | ||||
| Total current assets: | 299,463 | 89,500 | |||
| Noncurrent Assets | |||||
| Long-term investments and receivables | 230,021,238 | ||||
| Long-term investments | 230,021,238 | ||||
| Total noncurrent assets: | 230,021,238 | ||||
| TOTAL ASSETS: | 230,320,701 | 89,500 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 312,942 | ||||
| Other undisclosed accounts payable and accrued liabilities | 312,942 | ||||
| Due to related parties | 870 | 69,500 | |||
| Total current liabilities: | 313,812 | 69,500 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 8,650,000 | ||||
| Deferred compensation liability, classified | 8,650,000 | ||||
| Other undisclosed noncurrent liabilities | 18,505,400 | ||||
| Total noncurrent liabilities: | 27,155,400 | ||||
| Total liabilities: | 27,469,212 | 69,500 | |||
| Temporary equity, carrying amount | 230,021,238 | ||||
| Equity | |||||
| Equity, attributable to parent, including: | (27,169,749) | 20,000 | |||
| Common stock | 575 | ||||
| Additional paid in capital | 24,425 | ||||
| Accumulated deficit | (27,170,324) | (5,000) | |||
| Other undisclosed equity, attributable to parent | 575 | ||||
| Total equity: | (27,169,749) | 20,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 230,320,701 | 89,500 | |||
Income Statement (P&L) (USD)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Operating expenses | (1,570,165) | |||
| Operating loss: | (1,570,165) | |||
| Nonoperating income (Investment Income, Nonoperating) | 21,238 | |||
| Loss from continuing operations: | (1,548,927) | |||
| Loss before gain (loss) on sale of properties: | ✕ | (1,548,927) | ✕ | |
| Other undisclosed net loss | (5,315,654) | |||
| Net loss available to common stockholders, diluted: | (6,864,581) | |||
Comprehensive Income (USD)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Net loss: | (6,864,581) | |||
| Comprehensive loss, net of tax, attributable to parent: | (6,864,581) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.